Rheumatoid factors: Clinical applications

Disease Markers

Volumn 35, Issue 6, 2013, Pages 727-734

  Ingegnoli, Francesca ^a   Castelli, Roberto ^a   Gualtierotti, Roberta ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; RHEUMATOID FACTOR;

ARTHROPATHY; AUTOIMMUNE DISEASE; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; HUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT PLANNING;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; HUMANS; IMMUNOGLOBULIN G; PROGNOSIS; RHEUMATOID FACTOR;

EID: 84896949490     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/726598     Document Type: Review

References (92)

1. T. Dörner, K. Egerer, E. Feist, and G. R. Burmester, and "Rheumatoid factor revisited, and " Current Opinion in Rheumatology, vol. 16, no. 3, pp. 246-253, 2004.
2. E. Waaler, and "On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles, and " Acta Pathologica Microbiologica Scandinavica, vol. 17, no. 2, pp. 172-188, 1940.
3. H. M. Rose, C. Ragan et al. , and "Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis, and " Proceedings of the Society for Experimental Biology and Medicine, vol. 68, no. 1, pp. 1-6, 1948.
4. R. M. Pike, S. E. Sulkin, andH. C. Coggeshall, and "Serological reactions in rheumatoid arthritis; factors affecting the agglutination of sensitized sheep erythrocytes in rheumatid-arthritis serum, and " Journal of Immunology, vol. 63, no. 4, pp. 441-446, 1949.
5. J. Ball, K. J. Bloch, T. A. Burch, J. H. Kellgren, J. S. Lawrence, and V. Tsigalidou, and "Comparative studies of serologic tests for rheumatoid disease. II. A comparison of the bentonite flocculation test and the sensitized sheep cell agglutination test, and " Arthritis and Rheumatism, vol. 5, pp. 61-69, 1962.
6. J. Ball, R. De Graaff, H. A. Valkenburg, and F. W. Boerma, and "Comparative studies of serologic tests for rheumatoid disease. I. Acomparison of a latex test and two erythrocyte agglutination tests in a random population sample, and " Arthritis and Rheumatism, vol. 5, no. 1, pp. 55-60, 1962.
7. C. M. Plotz and J. M. Singer, and "The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis, and " The American Journal of Medicine, vol. 21, no. 6, pp. 888-892, 1956.
8. C. M. Plotz and J. M. Singer, and "The latex fixation test. II. Results in rheumatoid arthritis, and " The American Journal ofMedicine, vol. 21, no. 6, pp. 893-896, 1956.
9. K. Ailus, L. Melamies, T. Tuomi, T. Palosuo, and K. Aho, and "Measuring rheumatoid factor in nonrheumatoid subjects: immunoturbidimetric assay, latex slide test, and enzyme-linked immunosorbent assay compared, and " Clinical Chemistry, vol. 37, no. 10, part 1, pp. 1766-1769, 1991.
10. F. Wolfe, M. A. Cathey, and F. K. Roberts, and "The latex test revisited: rheumatoid factor testing in 8, 287 rheumatic disease patients, and " Arthritis and Rheumatism, vol. 34, no. 8, pp. 951-960, 1991.
11. J. G. Larkin, R. D. Sturrock, andW. H. Stimson, and "Arapid enzyme immunoassay for the detection of IgM rheumatoid factor. A comparison of sero-negative and sero-positive rheumatoid patients, and " Journal of Clinical and Laboratory Immunology, vol. 20, no. 4, pp. 207-209, 1986.
12. E. Ulvestad, L. L. Wilfred, and E. K. Kristoffersen, and "Measurement of IgM rheumatoid factor by ELISA, and " Scandinavian Journal of Rheumatology, vol. 30, no. 6, pp. 366-366, 2001.
13. I. Abreu, P. Laroche, A. Bastos et al. , and "Multiplexed immunoassay for detection of rheumatoid factors by FIDISTM technology, and " Annals of the New York Academy of Sciences, vol. 1050, pp. 357- 363, 2005.
14. D. F. LeGatt, G. B. Blakney, T. N. Higgins et al. , and "The effect of paraproteins and rheumatoid factor on four commercial immunoassays for vancomycin: implications for laboratorians and other health care professionals, and " Therapeutic DrugMonitoring, vol. 34, no. 3, pp. 306-311, 2012.
15. G. M. Surnamebartels and G. Surnameribel-Madsen, and "Cytokine measurements and possible interference from heterophilic antibodies-Problems and solutions experienced with rheumatoid factor, and " Methods, vol. 61, no. 1, pp. 18-22, 2013.
16. S. Miyakis, M. D. Lockshin, T. Atsumi et al. , and "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), and " Journal of Thrombosis and Haemostasis, vol. 4, no. 2, pp. 295-306, 2006.
17. G. Lakos, and "Interference in antiphospholipid antibody assays, and " Seminars inThrombosis and Hemostasis, vol. 38, no. 4, pp. 353- 359, 2012.
18. D. L. Stevenson, A. G. Harris, K. R. Neal, and W. L. Irving, and "The presence of rheumatoid factor in sera from anti-HCV positive blood donors interferes with the detection of HCVspecific IgM, and " Journal of Hepatology, vol. 25, no. 5, pp. 621-626, 1996.
19. O. H. Meurman and B. R. Ziola, and "IgM-class rheumatoid factor interference in the solid-phase radioimmunoassay of rubellaspecific IgM antibodies, and " Journal of Clinical Pathology, vol. 31, no. 5, pp. 483-487, 1978.
20. N. Després and A. M. Grant, and "Antibody interference in thyroid assays: a potential for clinical misinformation, and " Clinical Chemistry, vol. 44, no. 3, pp. 440-454, 1998.
21. A. M. Ramos-Levi, M. C. Montanez, I. Ortega, M. J. Cobo, and A. L. Calle-Pascual, and "A case of biochemical assay discrepancy: interference with measurement of thyroid-stimulating hormone due to rheumatoid factor, and " Endocrinología yNutrición, vol. 60, no. 6, pp. 342-345, 2013.
22. M. Berth, E. Bosmans, J. Everaert et al. , and "Rheumatoid factor interference in the determination of carbohydrate antigen 19- 9 (CA 19-9), and " Clinical Chemistry and Laboratory Medicine, vol. 44, no. 9, pp. 1137-1139, 2006.
23. E. Bartels, I. Falbe, E. Andersen, B. Danneskiold-Samsoe, H. Bliddal, and S. Ribel-Madsen, and "Rheumatoid factor and its interference with cytokine measurements: problems and solutions, and " Arthritis, vol. 2011, Article ID 741071, 7 pages, 2011.
24. M. M. Newkirk, and "Rheumatoid factors: host resistance or autoimmunity?" Clinical Immunology, vol. 104, no. 1, pp. 1-13, 2002.
25. R. H. Shmerling and T. L. Delbanco, and "Therheumatoid factor: an analysis of clinical utility, and " American Journal ofMedicine, vol. 91, no. 5, pp. 528-534, 1991.
26. O. M. R. Westwood, P. N. Nelson, and F. C. Hay, and "Rheumatoid factors: whats new?" Rheumatology, vol. 45, no. 4, pp. 379-385, 2006.
27. D. W. Dresser and A. M. Popham, and "Induction of an IgM anti (bovine) IgG response in mice by bacterial lipopolysaccharide, and " Nature, vol. 264, no. 5586, pp. 552-554, 1976.
28. L. Slaughter, D. A. Carson, and F. C. Jensen, and "In vitro effects of Epstein-Barr virus on peripheral blood mononuclear cells from patients with rheumatoid arthritis and normal subjects, and " Journal of Experimental Medicine, vol. 148, no. 5, pp. 1429-1434, 1978.
29. C. Palazzi, D. Buskila, S. DAngelo, E. DAmico, and I. Olivieri, and "Autoantibodies in patients with chronic hepatitis C virus infection: pitfalls for the diagnosis of rheumatic diseases, and " Autoimmunity Reviews, vol. 11, no. 9, pp. 659-663, 2011.
30. E. D. Charles, M. I. Orloff, E. Nishiuchi, S. Marukian, C. M. Rice, and L. B. Dustin, and "Somatic hypermutations confer rheumatoid factor activity in hepatitis C virus-associated mixed cryoglobulinemia, and " Arthritis and Rheumatism, vol. 65, no. 9, pp. 243-240, 2013.
31. M. Borretzen, C. Chapman, J. B. Natvig, and K. M. Thompson, and "Differences inmutational patterns between rheumatoid factors in health and disease are related to variable heavy chain family and germ-line gene usage, and " European Journal of Immunology, vol. 27, no. 3, pp. 735-741, 1997.
32. J. F. Simard andM. Holmqvist, and "Rheumatoid factor positivity in the general population, and " BritishMedical Journal, vol. 345, article e5841, 2012.
33. T. Tasliyurt, B. Kisacik, S. U. Kaya et al. , and "The frequency of antibodies against cyclic citrullinated peptides and rheumatoid factor in healthy population: a field study of rheumatoid arthritis from northern turkey, and " Rheumatology International, vol. 33, no. 4, pp. 939-942, 2013.
34. M. M. Newkirk, and "Rheumatoid factors: what do they tell us?" Journal of Rheumatology, vol. 29, no. 10, pp. 2034-2040, 2002.
35. L. T. H. Jacobsson, W. C. Knowler, S. Pillemer et al. , and "Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians, and "Arthritis and Rheumatism, vol. 36, no. 8, pp. 1045-1053, 1993.
36. T. Korpilähde, M. Heliövaara, O. Kaipiainen-Seppänen, P. Knekt, and K. Aho, and "Regional differences in Finland in the prevalence of rheumatoid factor in the presence and absence of arthritis, and " Annals of the Rheumatic Diseases, vol. 62, no. 4, pp. 353-355, 2003.
37. D. W. Dresser, and "Most IgM-producing cells in the mouse secrete auto-antibodies (rheumatoid factor), and " Nature, vol. 274, no. 5670, pp. 480-483, 1978.
38. S. F. Nielsen, S. E. Bojesen, P. Schnohr, and B. G. Nordestgaard, and "Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study, and " Britich Medical Journal, vol. 345, article e5244, 2012.
39. D. Van Schaardenburg, A. M. Lagaay, F. C. Breedveld, W. Hijmans, and J. P. Vandenbroucke, and "Rheumatoid arthritis in a population of persons aged 85 years and over, and " British Journal of Rheumatology, vol. 32, no. 2, pp. 104-109, 1993.
40. J. Ursum, W. H. Bos, R. J. Van de Stadt, B. A. C. Dijkmans, and D. Van Schaardenburg, and "Different properties ofACPAand IgMRF derived froma large dataset: further evidence of two distinct autoantibody systems, and " Arthritis Research and Therapy, vol. 11, no. 3, article R75, 2009.
41. C. Díaz-López, C. Geli, H. Corominas et al. , and "Are there clinical or serological differences between male and female patients with primary Sjögrens syndrome?" Journal of Rheumatology, vol. 31, no. 7, pp. 1352-1355, 2004.
42. D. Sansonno, G. Lauletta, L. Nisi et al. , and "Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia, and " Clinical and Experimental Immunology, vol. 133, no. 2, pp. 275-282, 2003.
43. Y. Masaki and S. Sugai, and "Lymphoproliferative disorders in Sjögrens syndrome, and " Autoimmunity Reviews, vol. 3, no. 3, pp. 175-182, 2004.
44. W. Swedler, J. Wallman, C. J. Froelich, and M. Teodorescu, and "Routine measurement of IgM, IgG, and IgA rheumatoid factors: high sensitivity, specificity, and predictive value for rheumatoid arthritis, and " Journal of Rheumatology, vol. 24, no. 6, pp. 1037-1044, 1997.
45. D. Aletaha, F. Alasti, and J. S. Smolen, and "Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity, and " Annals of the Rheumatic Diseases, vol. 72, no. 6, pp. 875-880, 2013.
46. K. Nishimura, D. Sugiyama, Y. Kogata et al. , and "Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis, and " Annals of Internal Medicine, vol. 146, no. 11, pp. 797-808, 2007.
47. V. P. K. Nell, K. P. Machold, T. A. Stamm et al. , and "Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis, and " Annals of the Rheumatic Diseases, vol. 64, no. 12, pp. 1731-1736, 2005.
48. N. J. Zvaifler, and "The immunopathology of joint inflammation in rheumatoid arthritis, and " Advances in Immunology, vol. 16, no. C, pp. 265-336, 1973.
49. A. M. Haberman, J. William, C. Euler, and M. J. Shlomchik, and "Rheumatoid factors in health and disease: structure, function, induction and regulation, and " Current Directions in Autoimmunity, vol. 6, pp. 169-195, 2003.
50. J. J. Stewart, H. Agosto, S. Litwin et al. , and "A solution to the rheumatoid factor paradox: pathologic rheumatoid factors can be tolerized by competition with natural rheumatoid factors, and " Journal of Immunology, vol. 159, no. 4, pp. 1728-1738, 1997.
51. D. M. Lee, D. S. Friend, M. F. Gurish, C. Benoist, D. Mathis, and M. B. Brenner, and "Mast cells: a cellular link between autoantibodies and inflammatory arthritis, and " Science, vol. 297, no. 5587, pp. 1689-1692, 2002.
52. R. A. Sweet, J. L. Cullen, and M. J. Shlomchik, and "Rheumatoid factor B cellmemory leads to rapid, switched antibody-forming cell responses, and " Journal of Immunology, vol. 190, no. 5, pp. 1974- 1981, 2013.
53. S. E. Burastero, P. Casali, R. L. Wilder, and A. L. Notkins, and "Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5+ B cells frompatients with rheumatoid arthritis, and " Journal of Experimental Medicine, vol. 168, no. 6, pp. 1979-1992, 1988.
54. H. W. Schroeder Jr. and L. Cavacini, and "Structure and function of immunoglobulins, and " Journal of Allergy and Clinical Immunology, vol. 125, no. 2, pp. S41-S52, 2010.
55. T. Jónsson, K. Steinsson, H. Jónsson, A. J. Geirsson, J. Thorsteinsson, and H. Valdimarsson, and "Combined elevation of IgM and IgA rheumatoid factor has high diagnostic specificity for rheumatoid arthritis, and " Rheumatology International, vol. 18, no. 3, pp. 119-122, 1998.
56. T. Jónsson and H. Valdimarsson, and "What about IgA rheumatoid factor in rheumatoid arthritis?" Annals of the Rheumatic Diseases, vol. 57, no. 1, pp. 63-64, 1998.
57. K. D. Deane, C. I. ODonnell, W. Hueber et al. , and "The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an agedependent manner, and " Arthritis and Rheumatism, vol. 62, no. 11, pp. 3161-3172, 2010.
58. A. Miller, K. R. Mahtani, M. A. Waterfield, A. Timms, S. A. Misbah, and R. A. Luqmani, and "Is rheumatoid factor useful in primary care? A retrospective cross-sectional study, and " Clinical Rheumatology, vol. 32, no. 7, pp. 1089-1093, 2013.
59. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al. , and "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, and " Arthritis and Rheumatism, vol. 31, no. 3, pp. 315-324, 1988.
60. D. Aletaha, T. Neogi, A. J. Silman et al. , and "2010 Rheumatoid arthritis classification criteria: an AmericanCollege ofRheumatology/ European League Against Rheumatism collaborative initiative, and " Arthritis and Rheumatism, vol. 62, no. 9, pp. 2569- 2581, 2010.
61. S. Bas, S. Genevay, O. Meyer, and C. Gabay, and "Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis, and " Rheumatology, vol. 42, no. 5, pp. 677-680, 2003.
62. S. Rantapää-Dahlqvist, B. A. W. De Jong, E. Berglin et al. , and "Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis, and " Arthritis and Rheumatism, vol. 48, no. 10, pp. 2741-2749, 2003.
63. B. E. Gilliam and T. L. Moore, and "The role of anti-cyclic citrullinated peptide (CCP) antibodies in early detection of rheumatoid arthritis: an overview of the INOVA Diagnostics, Inc. QUANTA Lite CCP assays, and " Expert Opinion on Medical Diagnostics, vol. 6, no. 4, pp. 359-369, 2012.
64. D. Manivelavan and C. K. Vijayasamundeeswari, and "Anti-cyclic citrullinated peptide antibody: an early diagnostic and prognostic biomarker of rheumatoid arthritis, and " Journal of Clinical and Diagnostic Research, vol. 6, no. 8, pp. 1393-1396, 2012.
65. C. Peoples, R. Valiyil, R. B. Davis, and R. H. Shmerling, and "Clinical use of anti-cyclic citrullinated Peptide antibody testing, and " Journal of Clinical Rheumatology, vol. 19, no. 6, pp. 351-352, 2013.
66. M. K. Demoruelle, M. C. Parish, L. A. Derber et al. , and "Anti-cyclic citrullinated peptide assays differ in subjects at elevated risk for rheumatoid arthritis and subjects with established disease, and " Arthritis and Rheumatism, vol. 65, no. 9, pp. 2243-2252, 2013.
67. F. Debaugnies, G. Servais, V. Badot, D. Noubouossie, D. Willems, and F. Corazza, and "Anti-cyclic citrullinated peptide antibodies: a comparison of different assays for the diagnosis of rheumatoid arthritis, and " Scandinavian Journal of Rheumatology, vol. 42, no. 2, pp. 108-114, 2013.
68. S. Rantapää-Dahlqvist, and "What happens before the onset of rheumatoid arthritis?" Current Opinion in Rheumatology, vol. 21, no. 3, pp. 272-278, 2009.
69. K. D. Deane, J. M. Norris, and V. M. Holers, and "Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation, and " Rheumatic Disease Clinics of North America, vol. 36, no. 2, pp. 213-241, 2010.
70. T. Tillmann, R. Krishnadas, J. Cavanagh, and K. Petrides, and "Possible rheumatoid arthritis subtypes in terms of rheumatoid factor, depression, diagnostic delay and emotional expression: an exploratory case-control study, and " Arthritis Research and Therapy, vol. 15, no. 2, article R45, 2013.
71. L. Barra, V. Bykerk, J. E. Pope et al. , and "Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes, and " Journal of Rheumatology, vol. 40, no. 8, pp. 1259-1267, 2013.
72. T. R. Mikuls, J. R. ODell, J. A. Stoner et al. , and "Association of rheumatoid arthritis treatment response and disease duration with declines in serumlevels of IgMrheumatoid factor and anticyclic citrullinated peptide antibody, and " Arthritis and Rheumatism, vol. 50, no. 12, pp. 3776-3782, 2004.
73. F. Bobbio-Pallavicini, C. Alpini, R. Caporali, S. Avalle, S. Bugatti, and C. Montecucco, and "Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment, and " Arthritis research and therapy, vol. 6, no. 3, pp. R264-272, 2004.
74. L. De Rycke, X. Verhelst, E. Kruithof et al. , and "Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis, and " Annals of the Rheumatic Diseases, vol. 64, no. 2, pp. 299-302, 2005.
75. P. Caramaschi, D. Biasi, E. Tonolli et al. , and "Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment, and " Rheumatology International, vol. 26, no. 1, pp. 58-62, 2005.
76. H. A. Chen, K. C. Lin, C. H. Chen et al. , and "The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis, and " Annals of the Rheumatic Diseases, vol. 65, no. 1, pp. 35-39, 2006.
77. F. Atzeni, P. Sarzi-Puttini, D. Dell Acqua et al. , and "Adalimumab clinical efficacy is associated with rheumatoid factor and anticyclic citrullinated peptide antibody titer reduction: a one-year prospective study, and " Arthritis Research and Therapy, vol. 8, no. 1, article R3, 2006.
78. G. Cambridge, M. J. Leandro, J. C. W. Edwards et al. , and "Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis, and " Arthritis and Rheumatism, vol. 48, no. 8, pp. 2146-2154, 2003.
79. S. B. Cohen, P. Emery, M. W. Greenwald et al. , and "Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks, and " Arthritis and Rheumatism, vol. 54, no. 9, pp. 2793-2806, 2006.
80. R. J. Maneiro, E. Salgado, L. Carmona, and J. J. Gomez-Reino, and "Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis, and " Seminars in Arthritis and Rheumatism, vol. 43, no. 1, pp. 9-17, 2013.
81. C. Faillace and J. F. deCarvalho, and "Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis, and " Rheumatology International, pp. 1909-1910, 2013.
82. K. L. Hyrich, K. D. Watson, A. J. Silman, andD. P. M. Symmons, and "Predictors of response to anti-TNF- therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register, and " Rheumatology, vol. 45, no. 12, pp. 1558-1565, 2006.
83. W. H. Bos, G. M. Bartelds, G. J. Wolbink et al. , and "Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis, and " Journal of Rheumatology, vol. 35, no. 10, pp. 1972-1977, 2008.
84. E. Salgado, J. R. Maneiro, L. Carmona, and J. Gomez-Reino, and "nd response to TNF antagonists in rheumatoid arthritis: systematic review and meta-analysis of observational studies, and " Joint Bone Spine, 2013.
85. E. Salgado, J. R. Maneiro, L. Carmona, and J. J. Gomez- Reino, and "Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis, and " Annals of the Rheumatic Diseases, 2013.
86. R. Klaasen, T. Cantaert, C. A. Wijbrandts et al. , and "The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study, and " Rheumatology, vol. 50, no. 8, pp. 1487-1493, 2011.
87. C. Potter, K. L. Hyrich, A. Tracey et al. , and "Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis, and " Annals of the Rheumatic Diseases, vol. 68, no. 1, pp. 69-74, 2009.
88. F. Bobbio-Pallavicini, R. Caporali, C. Alpini, R. Moratti, and C. Montecucco, and "Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF- treated patients, and " Annals of the New York Academy of Sciences, vol. 1109, pp. 287-295, 2007.
89. J. C. W. Edwards, L. Szczepański, J. Szechiński et al. , and "Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis, and "TheNew England Journal ofMedicine, vol. 350, no. 25, pp. 2572-2581, 2004.
90. L. Quartuccio, M. Fabris, S. Salvin et al. , and "Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis, and " Rheumatology, vol. 48, no. 12, pp. 1557-1559, 2009.
91. J. D. Isaacs, S. B. Cohen, P. Emery et al. , and "Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis, and " Annals of the Rheumatic Diseases, vol. 72, no. 3, pp. 329-336, 2013.
92. J. D. Jones, I. Shyu, M. M. Newkirk, and W. F. Rigby, and "A rheumatoid factor paradox: inhibition of rituximab effector function, and " Arthritis Research and Therapy, vol. 15, no. 1, article R20, 2013.